Trying 3106016892...Open

Trying 3106016892...Open

Welcome to STN International! Enter x:x
LOGINID:ssspta1653hxp
PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1	Feb 2	Web Page URLs for STN Seminar Schedule - N. America
NEWS	2	Dec 17	Expanded CAplus Coverage of US, Japanese, WIPO, EPO, and German patents
NEWS	3	Feb 1	Addition of Machine-Translated Abstracts to CAplus
NEWS	4	Feb 28	Patent Information Now Searchable in CAOLD SDI/UPDATE SEARCH FIELD
NEWS	5	May 1	Beilstein Abstracts on STN - FILE BABS
NEWS	6	May 1	RN CROSSOVER AND ANSWER SIZE LIMITS INCREASED
NEWS	7	May 1	AIDSLINE has been reloaded
NEWS	8	May 1	Searching Y2-K compliant Patent Numbers
NEWS	9	May 9	Sequence Similarity Batch Search in DGENE
NEWS	10	May 19	Weekly Statistics for New Entries now available in INPADOC
NEWS	11	May 22	CITED REFERENCES NOW AVAILABLE IN CAPLUS AND CA FILE
NEWS	12	May 22	POSTPROCESSING OF SEARCH RESULTS MAY BE AFFECTED BY ADDITION OF CITED REFERENCES TO CAPLUS, CA, REGISTRY, CASREACT, MARPAT, and MARPATPREV
NEWS	13	Jun 2	KOREAN PATENTS NOW IN CAS DATABASES
NEWS	14	Jun 20	WIPO/PCT Patents Fulltext Database now on STN
NEWS	15	Jun 28	NEWS 15 Jun 28 CAS covers Web-distributed preprints
NEWS	EXPRESS		FREE UPGRADE 5.0C NOW AVAILABLE
NEWS	HOURS		STN Operating Hours Plus Help Desk Availability
NEWS	INTER		General Internet Information
NEWS	LOGIN		Welcome Banner and News Items
NEWS	PHONE		Direct Dial and Telecommunication Network Access to STN
NEWS	WWW		CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 16:16:14 ON 02 JUL 2000

=> file medline, biosis, uspat, scisearch

COST IN U.S. DOLLARS SINCE FILE TOTAL

FULL ESTIMATED COST | ENTRY 15 | SESSION 0.45

FILE 'MEDLINE' ENTERED AT 16:17:57 ON 02 JUL 2000

FILE 'BIOSIS' ENTERED AT 16:17:57 ON 02 JUL 2000
COPYRIGHT (C) 2000 BIOSIS(R)

FILE 'USPATFULL' ENTERED AT 16:17:57 ON 02 JUL 2000
CA INDEXING COPYRIGHT (C) 2000 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'SCISEARCH' ENTERED AT 16:17:57 ON 02 JUL 2000
COPYRIGHT (C) 2000 Institute for Scientific Information (ISI) (R)

=> s autoimmune disease adj method

L1 0 AUTOIMMUNE DISEASE ADJ METHOD

=> s autoimmune disease

L2 24420 AUTOIMMUNE DISEASE

=> s l2 and method

L3 3743 L2 AND METHOD

=> s l3 and immunosuppressive drug

L4 64 L3 AND IMMUNOSUPPRESSIVE DRUG

=> s l4 and rapamycin

L5 25 L4 AND RAPAMYCIN

=> d l5 ti abs ibib tot

L5 ANSWER 1 OF 25 USPATFULL
TI Flavone analogues useful as anti-rejection agents
AB Flavone analogues of formula ##STR1## wherein; X is O or S;

R.sub.1 is C.sub.1 -C.sub.6 alkyl or C.sub.2 -C.sub.6 alkenyl;

R.sub.2 is H, C.sub.1 -C.sub.6 alkyl or R.sub.2 O is a sugar residue;

R.sub.3 is H, C.sub.1 -C.sub.6 alkyl or R.sub.3 O is a sugar residue;

R.sub.4 is H, OH, or a sugar residue;

R.sub.5 is H, C.sub.1 -C.sub.6 alkyl, or R.sub.5 O is a sugar residue;

m is an integer of 1 or 2; and

n is an integer from 0 to 5,

are useful as anti-rejection agents in organ transplants.

ACCESSION NUMBER: 2000:70813 USPATFULL
TITLE: Flavone analogues useful as anti-rejection agents
INVENTOR(S): Chen, Huifang, 271 Inglewood Ave., Point-Claire, Quebec, Canada H9R 2Z3
Li, Feng, 506 Boul. St-Jean, Apt. 200, Pointe-Claire, Quebec, Canada H9R 3J6
Liu, Luwei, 30 Eaton Ave., Kirkland, Quebec, Canada

	NUMBER	DATE
PATENT INFORMATION:	US 6071883	20000606
APPLICATION INFO.:	US 1998-123313	19980728 (9)

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Peselev, Elli
LEGAL REPRESENTATIVE: Renault, Swabey Ogilvy; Murphy, Kevin P.
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Figure(s); 1 Drawing Page(s)
LINE COUNT: 362

L5 ANSWER 2 OF 25 USPATFULL
TI Immunomodulators and methods for the prevention and reversal of organ transplant rejection using same
AB Compounds and methods are described for the differential inhibition of tyrosine phosphorylation of phospholipase C-.gamma.1 for the prevention or reversal of transplant rejection as well as therapy for autoimmune diseases. Methods for the treating or preventing tissue or organ transplant rejection and methods for treating an **autoimmune disease** comprising the administration of monoclonal antibodies that specifically bind to the CD45RB epitope of the CD45RB isoform are disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2000:18045 USPATFULL
TITLE: Immunomodulators and methods for the prevention and reversal of organ transplant rejection using same
INVENTOR(S): Lazarovits, Andrew I., London, Canada
Poppema, Sibrand, Edmonton, Canada
PATENT ASSIGNEE(S): Research Corporation Technologies, Inc., Tucson, AZ, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 6024957	20000215
APPLICATION INFO.:	US 1995-423843	19950418 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1993-71009, filed on 2 Jun 1993, now abandoned
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Feisee, Lila
ASSISTANT EXAMINER: Johnson, Nancy A.
LEGAL REPRESENTATIVE: Schwegman, Lundberg, Woessner & Kluth, P.A.
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1,18
NUMBER OF DRAWINGS: 13 Drawing Figure(s); 5 Drawing Page(s)
LINE COUNT: 1198
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 3 OF 25 USPATFULL
TI Use of hyaluronic acid as an immunosuppressant
AB A pharmaceutical formulation of hyaluronic acid is administered to a patient suffering from undesirable T cellactivity. The hyaluronic acid inhibits T cell activity at doses that are well-tolerated by the recipient. Conditions suitable for treatment include graft vs. host disease, graft rejection and certain autoimmune diseases having a T cell component.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2000:4803 USPATFULL
TITLE: Use of hyaluronic acid as an immunosuppressant

INVENTOR(S): Lussow, Alexander R., Menlo Park, CA, United States
[redacted]uelow, Roland, Palo Alto, CA, United States
PATENT ASSIGNEE(S): [redacted]angStat Medical Corporation, Fr[redacted]ont, CA, United States (U.S. corporation)

	NUMBER	DATE	
PATENT INFORMATION:	US 6013641	20000111	
APPLICATION INFO.:	US 1996-721835	19960927	(8)
	NUMBER	DATE	
PRIORITY INFORMATION:	US 1995-4468	19950928	(60)

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Wortman, Donna
ASSISTANT EXAMINER: Brumback, Brenda G.
LEGAL REPRESENTATIVE: Trecartin, Richard F.; Lorenz, Todd A.Albritton & Herbert LLP
NUMBER OF CLAIMS: 11
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT: 593
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 4 OF 25 USPATFULL
TI Immunosuppressive compounds and methods
AB Compounds and methods for use in immunosuppressive and anti-inflammatory
treatment, and for inhibiting male fertility, are described. The compounds are triptolide analogs with improved water solubility and low toxicity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 1999:121418 USPATFULL
TITLE: Immunosuppressive compounds and methods
INVENTOR(S): Qi, You Mao, Los Altos, CA, United States
Musser, John H., San Carlos, CA, United States
Fidler, John M., Oakland, CA, United States
PATENT ASSIGNEE(S): Pharmagenesis, Inc., Palo Alto, CA, United States (U.S.
corporation)

	NUMBER	DATE	
PATENT INFORMATION:	US 5962516	19991005	
	WO 9731921	19970904	
APPLICATION INFO.:	US 1999-142128	19990125	(9)
	WO 1997-US3202	19970228	
		19990125	PCT 371 date
		19990125	PCT 102(e) date

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Reamer, James H.
LEGAL REPRESENTATIVE: Gorthey, LeeAnn; Powers, Vincent M.
NUMBER OF CLAIMS: 11
EXEMPLARY CLAIM: 1,4
NUMBER OF DRAWINGS: 9 Drawing Figure(s); 8 Drawing Page(s)
LINE COUNT: 1309
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 5 OF 25 USPATFULL
TI Treatment methods for disease using co-localized cells and Sertoli cells
obtained from a cell line
AB A **method** of treating a disease is provided that results from a

deficiency of a biclogical factor which comprises administering to a mammal Sertoli cells and cells that produce the biological factor. A **method** of treating diabetes mellitus is carried out transplanting pancreatic islet of Langerhans cells in conjunction with Sertoli cells to create an immunologically privileged site. A **method** of creating an immunologically privileged site and providing cell stimulatory factors in a mammal for transplants is also carried out. A **method** of co-localizing islet cells with Sertoli cells and the use of the co-localized product for treating diabetes mellitus is further provided. Further described is a **method** of creating systemic tolerance to foreign antigens. A **method** of enhancing the viability, maturation, proliferation of functional capacity of cells in tissue culture is also provided. In addition, a pharmaceutical composition comprising Sertoli cells and cells that produce a biological factor is provided.

ACCESSION NUMBER: 1999:116976 USPATFULL
TITLE: Treatment methods for disease using co-localized cells and Sertoli cells obtained from a cell line
INVENTOR(S): Selawry, Helena P., Rileyville, VA, United States
PATENT ASSIGNEE(S): Research Corporation Technologies, Inc., Tucson, AZ, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5958404	19990928
APPLICATION INFO.:	US 1996-660258	19960607 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1995-485340, filed on 7 Jun 1995, now patented, Pat. No. US 5849285 which is a continuation-in-part of Ser. No. US 1995-421641, filed on 13 Apr 1995, now patented, Pat. No. US 5725854 which is a continuation-in-part of Ser. No. US 1994-211695, filed on 13 Apr 1994, now abandoned

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Naff, David M.
ASSISTANT EXAMINER: Ware, Deborah K.
LEGAL REPRESENTATIVE: Scully, Scott Murphy & Presser
NUMBER OF CLAIMS: 50
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 14 Drawing Figure(s); 12 Drawing Page(s)
LINE COUNT: 2027

L5 ANSWER 6 OF 25 USPATFULL
TI Methods and compounds for prevention of graft rejection
AB Disclosed is a **method** of localized immunosuppression which may be used for preventing graft rejection or for preventing tissue destruction due to **autoimmune disease**. Also disclosed is a protein suppressor factor that is secreted by cloned anergic T-cells, blocks interleukin 2 (IL-2) stimulated T-cell proliferation, has an apparent molecular weight of between 10 and 30 kilodaltons, can be inactivated by heating to 65.degree. C. for 15 minute, blocks interleukin 4 (IL-4) stimulated T-cell proliferation in vitro, is non-cytotoxic to T-cells, and does not inhibit the production of IL-2 by T-cells in vitro.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 1999:116975 USPATFULL
TITLE: Methods and compounds for prevention of graft rejection
INVENTOR(S): Strom, Terry, Brookline, MA, United States
Libermann, Towia, Newton, MA, United States
PATENT ASSIGNEE(S): Beth Israel Hospital Association, Boston, MA, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5958403	19990928
APPLICATION INFO.:	US 1994-273402	19940711 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1993-24569, filed on 1 Mar 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-843731, filed on 28 Feb 1992, now abandoned

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Stanton, Brian R.
ASSISTANT EXAMINER: Hauda, Karen M.
LEGAL REPRESENTATIVE: Fish & Richardson P.C.
NUMBER OF CLAIMS: 1
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 30 Drawing Figure(s); 16 Drawing Page(s)
LINE COUNT: 2143
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 7 OF 25 USPATFULL

TI **Autoimmune disease** treatment with sertoli cells and in vitro co-culture of mammal cells with sertoli cells

AB The present invention describes a **method** of treating a disease that results from a deficiency of a biological factor which comprises administering to a mammal Sertoli cells and cells that produce the biological factor. In particular, the present invention describes a **method** of treating diabetes mellitus by transplanting pancreatic islet of Langerhans cells in conjunction with Sertoli cells to create an immunologically privileged site. A **method** of creating an immunologically privileged site and providing cell stimulatory factors in a mammal for transplants is further described by the present invention. The present invention further describes a **method** of creating systemic tolerance to foreign antigens. A **method** of enhancing the viability, maturation, proliferation of functional capacity of cells in tissue culture is further provided. A pharmaceutical composition comprising Sertoli cells and cells that produce a biological factor is also provided. In addition treatment of an **autoimmune disease** via the transplantation of Sertoli cells alone into a transplant site other than the testes is disclosed. The dosage amount of Sertoli cells administered ranges from 10.sup.5 to 10.sup.10 cells. Also an in vitro **method** of accelerating the maturation and increasing the proliferation and functional capacity of proliferating mammalian cells via the co-culturing of the mammalian cells with Sertoli cells is disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 1998:156909 USPATFULL
TITLE: **Autoimmune disease** treatment with sertoli cells and in vitro co-culture of mammal cells with sertoli cells
INVENTOR(S): Selawry, Helena P., Memphis, TN, United States
PATENT ASSIGNEE(S): Research Corporation Technologies, Inc., Tucson, AZ, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5849285	19981215
APPLICATION INFO.:	US 1995-485340	19950607 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1995-421641, filed on 13 Apr 1995, now patented, Pat. No. US 5725854 which is a continuation-in-part of Ser. No. US 1994-211695, filed on 13 Apr 1994, now abandoned

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Naff, David M.
ASSISTANT EXAMINER: Ware, Deborah K.
LEGAL REPRESENTATIVE: Scully, Scott, Murphy & Presser
NUMBER OF CLAIMS: 7
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 14 Drawing Figure(s); 12 Drawing Page(s)
LINE COUNT: 1599
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 8 OF 25 USPATFULL
TI Immunotherapy composition and **method**
AB A composition for use in immunosuppression therapy is disclosed. The composition includes an immunosuppressant drug, such as cyclosporin A, and an ethanol extract of the root xylem of Tripterygium wilfordii. The extract is effective alone, or in combination with such an immunosuppressant, in the treatment of transplantation rejection. Also disclosed is a **method** of immunosuppression that includes administering to a subject a pharmaceutically effective amount of an immunosuppressant drug and an extract of the type above, in an amount effective to potentiate the action of the drug.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 1998:150472 USPATFULL
TITLE: Immunotherapy composition and **method**
INVENTOR(S): Wiedmann, Tien-Wen Tao, Redwood City, CA, United States
Wang, Jian, Palo Alto, CA, United States
Pliam, Nathan B., Palo Alto, CA, United States
Wuh, Hank C. K., Los Altos, CA, United States
PATENT ASSIGNEE(S): Pharmagenesis, Inc., Palo Alto, CA, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5843452	19981201
APPLICATION INFO.:	US 1994-252953	19940602 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1992-973634, filed on 9 Nov 1992, now abandoned
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Rollins, John W.
LEGAL REPRESENTATIVE: Dehlinger, Peter J.; Powers, Vincent M.
NUMBER OF CLAIMS: 7
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 11 Drawing Figure(s); 11 Drawing Page(s)
LINE COUNT: 1152
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 9 OF 25 USPATFULL
TI **Method** for suppressing xenograft rejection
AB An improved **method** for suppressing xenograft rejection in a host subject is disclosed. The **method** includes administering an immunosuppressant drug, where the drug or the amount of drug administered is, by itself, ineffective to suppress xenograft rejection.
Effective xenograft suppression is achieved by also administering an ethanolic extract of Triterygium wilfordii or a purified triptolide component thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 1998:61170 USPATFULL
TITLE: **Method** for suppressing xenograft rejection
INVENTOR(S): Wiedmann, Tien Wen Tao, Redwood City, CA, United States

PATENT ASSIGNEE(S): Wang, Jian, Palo Alto, CA, United States
Pharmagenesis, Inc., Palo Alto, CA, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5759550	19980602
APPLICATION INFO.:	US 1995-484782	19950607 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1994-307948, filed on 15 Sep 1994, now abandoned which is a continuation-in-part of Ser. No. US 1994-222853, filed on 5 Apr 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-58321, filed on 6 May 1993, now abandoned And a continuation-in-part of Ser. No. US 1994-252953, filed on 2 Jun 1994, now abandoned

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Rollins, John W.
LEGAL REPRESENTATIVE: Powers, Vincent M.; Gorthey, LeeAnn
NUMBER OF CLAIMS: 10
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 25 Drawing Figure(s); 18 Drawing Page(s)
LINE COUNT: 1249
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 10 OF 25 USPATFULL
TI Aromatic compounds for inhibiting immune response
AB Novel compounds ##STR1## wherein R.sup.1 to R.sup.13 are independently selected from C.sub.2 -C.sub.4 linear and branched alkyls, H, NH.sub.2, CH.sub.3, OR.sup.14, fluorine, chlorine, iodine, NO.sub.2, CF.sub.3, NHCOCH.sub.3, NHCOOtBu, NHR.sup.15, NR.sup.16 R.sup.17 and phenyl, for use as immunosuppressive agents to prevent or significantly reduce graft rejection in organ and bone marrow transplantation are described. The novel compounds can also be used as an immunosuppressant drug for T-lymphocyte mediated autoimmune diseases, such as diabetes, and may be useful in alleviating psoriasis and contact dermatitis. Additionally, the novel compounds can be used for antiproliferation and gene therapy.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 1998:39559 USPATFULL
TITLE: Aromatic compounds for inhibiting immune response
INVENTOR(S): Ocain, Timothy D., Framingham, MA, United States
Gao, Huai, Groton, MA, United States
Krieger, Jeffrey I., Newton, MA, United States
Sampo, Theresa M., Boston, MA, United States
PATENT ASSIGNEE(S): Procept, Incorporated, Cambridge, MA, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5739169	19980414
APPLICATION INFO.:	US 1996-656468	19960531 (8)

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Shah, Mukund J.
ASSISTANT EXAMINER: Kifle, Bruck
LEGAL REPRESENTATIVE: Hamilton, Brook, Smith and Reynolds, P.C.
NUMBER OF CLAIMS: 5
EXEMPLARY CLAIM: 1
LINE COUNT: 670
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 11 OF 25 USPATFULL
TI Biologically active acylated amino acid derivatives
AB The present invention relates to novel compounds which possess a broad range of useful biological activities. These compounds can maintain, increase, or restore sensitivity of cells to therapeutic or prophylactic agents. They can also suppress, modify, or significantly reduce an immune response, including an autoimmune response in a mammal. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well-suited for treatment of multi-drug resistant cells, for prevention of the development of multi-drug resistance, for use in multi-drug resistant cancer therapy, and for prevention or treatment of graft rejection and various autoimmune diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	1998:22219 USPATFULL
TITLE:	Biologically active acylated amino acid derivatives
INVENTOR(S):	Armistead, David M., Maynard, MA, United States Harding, Matthew W., Acton, MA, United States Saunders, Jeffrey O., Acton, MA, United States Boger, Joshua S., Concord, MA, United States
PATENT ASSIGNEE(S):	Vertex Pharmaceuticals Incorporated, Cambridge, MA, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5723459	19980303
APPLICATION INFO.:	US 1995-377315	19950124 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1994-217982, filed on 25 Mar 1994, now patented, Pat. No. US 5620971 And Ser. No. US 1992-881152, filed on 11 May 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-697785, filed on 9 May 1991, now abandoned , said Ser. No. US -217982 which is a continuation-in-part of Ser. No. US 1993-127814, filed on 28 Sep 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-952299, filed on 28 Sep 1992, now abandoned	
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Grumbling, Matthew V.	
LEGAL REPRESENTATIVE:	Fish & Neave; Haley, Jr., James F.; Marks, Andrew S.	
NUMBER OF CLAIMS:	28	
EXEMPLARY CLAIM:	1	
LINE COUNT:	3231	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 12 OF 25 USPATFULL
TI **Method** for inhibiting immune response
AB Use of ruthenium complexes as immunosuppressive agents to prevent or significantly reduce graft rejection in organ and bone marrow transplantation is described. The ruthenium complexes can also be used as immunosuppressant drugs for T-lymphocyte mediated autoimmune diseases, such as diabetes, and may be useful in alleviating psoriasis and contact dermatitis. The ruthenium complexes can also be used therapeutically in the treatment of hyperproliferative vascular disease.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	1998:4621 USPATFULL
TITLE:	**Method** for inhibiting immune response
INVENTOR(S):	Bastos, Cecilia M., Marlborough, MA, United States Ocain, Timothy D., Framingham, MA, United States

PATENT ASSIGNEE(S): Procept, Inc., Cambridge, MA, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5708022	19980113
APPLICATION INFO.:	US 1995-482308	19950607 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1994-331204, filed on 28 Oct 1994, now abandoned
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Criares, Theodore J.
LEGAL REPRESENTATIVE: Hamilton, Brook, Smith & Reynolds, P.C.
NUMBER OF CLAIMS: 28
EXEMPLARY CLAIM: 1
LINE COUNT: 771
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 13 OF 25 USPATFULL
TI Use of leflunomide to prevent or control xenograft rejection
AB The present invention relates to methods of controlling or reversing chronic rejection of allografts in a transplantation patient by administering leflunomide product alone, or in combination with one or more immunosuppressive agents selected from the group consisting of Cyclosporine A, FK506, **rapamycin** and corticosteroids. The invention also relates to methods of preventing or controlling acute and chronic rejection of xenografts in a transplantation patient by administering leflunomide product alone, or in combination with one or more immunosuppressive agents selected from the group consisting of Cyclosporine A, FK506, **rapamycin** and corticosteroids.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 97:107110 USPATFULL
TITLE: Use of leflunomide to prevent or control xenograft rejection
INVENTOR(S): Williams, James, 655 Superior, Oak Park, IL, United States 60302

	NUMBER	DATE
PATENT INFORMATION:	US 5688824	19971118
APPLICATION INFO.:	US 1996-598149	19960207 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1994-270908, filed on 5 Jul 1994, now patented, Pat. No. US 5624946
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Criares, Theodore J.
LEGAL REPRESENTATIVE: Marshall, O'Toole, Gerstein, Murray & Borun
NUMBER OF CLAIMS: 12
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Figure(s); 3 Drawing Page(s)
LINE COUNT: 1369
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 14 OF 25 USPATFULL
TI Immunosuppressive compounds
AB This invention relates to a novel class of immunosuppressive compounds having an affinity for the FK-506 binding protein (FKBP). Once bound to this protein, the immunosuppressive compounds inhibit the prolyl peptidyl cis-trans isomerase (rotamase) activity of the FKBP and inhibit T cell activation. As such, the compounds of this invention can be used as immunosuppressive drugs to prevent or significantly reduce graft rejection in bone marrow and organ transplantations and for use in the treatment of a wide variety of autoimmune diseases in humans and other

mammals.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 97:81322 USPATFULL
TITLE: Immunosuppressive compounds
INVENTOR(S): Armistead, David M., 5 Cutting Dr., Maynard, MA, United States 01754
Boger, Joshua S., 243 Old Pickard Rd., Concord, MA, United States 01742
Meyers, Harold V., 208 Katahdin Dr., Lexington, MA, United States 01273
Saunders, Jeffrey O., 71 New Estate Rd., Littleton, MA, United States 01460
Tung, Roger D., 2561 Massachusetts Ave. #2, Cambridge, MA, United States 02140

	NUMBER	DATE
PATENT INFORMATION:	US 5665774	19970909
APPLICATION INFO.:	US 1993-27870	19930308 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1990-547814, filed on 2 Jul 1990, now patented, Pat. No. US 5192773
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Dentz, Bernard
LEGAL REPRESENTATIVE: Fish & Neave; Haley, Jr., James F.; Marks, Andrew S.
NUMBER OF CLAIMS: 18
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 10 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT: 1143
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 15 OF 25 USPATFULL
TI Use of leflunomide to control and reverse chronic allograft rejection
AB The present invention relates to methods of controlling or reversing chronic rejection of allografts in a transplantation patient by administering leflunomide product alone, or in combination with one or more immunosuppressive agents selected from the group consisting of Cyclosporine A, FK506, **rapamycin** and corticosteroids. The invention also relates to methods of preventing or controlling acute and chronic rejection of xenografts in a transplantation patient by administering leflunomide product alone, or in combination with one or more immunosuppressive agents selected from the group consisting of Cyclosporine A, FK506, **rapamycin** and corticosteroids.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 97:36206 USPATFULL
TITLE: Use of leflunomide to control and reverse chronic allograft rejection
INVENTOR(S): Williams, James, 655 Superior, Oak Park, IL, United States 60302

	NUMBER	DATE
PATENT INFORMATION:	US 5624946	19970429
APPLICATION INFO.:	US 1994-270908	19940705 (8)

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Criares, Theodore J.
LEGAL REPRESENTATIVE: Marshall, O'Toole, Gerstein, Murray & Borun
NUMBER OF CLAIMS: 11
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Figure(s); 3 Drawing Page(s)

LINE COUNT: 1354
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 16 OF 25 USPATFULL
TI Immunosuppressive compounds
AB This invention relates to a novel class of immunosuppressive compounds having an affinity for the FK-506 binding protein (FKBP). Once bound to this protein, the immunosuppressive compounds inhibit the prolyl peptidyl cis-trans isomerase (rotamase) activity of the FKBP and inhibit T cell activation. As such, the compounds of this invention can be used as immunosuppressive drugs to prevent or significantly reduce graft rejection in bone marrow and organ transplantations and for use in the treatment of a wide variety of autoimmune diseases in humans and other mammals.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 97:33765 USPATFULL
TITLE: Immunosuppressive compounds
INVENTOR(S): Armistead, David A., Maynard, MA, United States
Boger, Joshua S., Concord, MA, United States
Meyers, Harold V., Lexington, MA, United States
Saunders, Jeffrey O., Littleton, MA, United States
Tung, Roger D., Cambridge, MA, United States
PATENT ASSIGNEE(S): Vertex Pharmaceuticals, Incorporated, Cambridge, MA, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5622970	19970422
APPLICATION INFO.:	US 1995-456572	19950601 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1993-27870, filed on 8 Mar 1993
which is a division of Ser. No. US 1990-547814, filed on 2 Jul 1990, now patented, Pat. No. US 5192773
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Dentz, Bernard
LEGAL REPRESENTATIVE: Fish & Neave; Haley, Jr., James F.; Marks, Andrew S.
NUMBER OF CLAIMS: 10
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 10 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT: 1031
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 17 OF 25 USPATFULL
TI **Method** for treating a LFA-1-mediated disorder
AB A **method** is provided for administering to a mammal suffering from, or at risk for, a LFA-1-mediated disorder an initial dosing of a therapeutically effective amount of LFA-1 antagonist, followed by a subsequent intermittent dosing of a therapeutically effective amount of LFA-1 antagonist that is less than 100%, calculated on a daily basis, of the initial dosing of antagonist.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 97:33495 USPATFULL
TITLE: **Method** for treating a LFA-1-mediated disorder
INVENTOR(S): Jardieu, Paula M., Berkeley, CA, United States
Montgomery, Bruce, Redwood City, CA, United States
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States
(U.S. corporation)

	NUMBER	DATE

	NUMBER	DATE
PATENT INFORMATION:	US 5622700	19970422
APPLICATION INFO.:	US 1995-432543	19950502 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1994-287055, filed on 8 Aug 1994 which is a continuation of Ser. No. US 1993-128329, filed on 28 Sep 1993, now abandoned which is a continuation of Ser. No. US 1992-933269, filed on 21 Aug 1992, now abandoned

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Chan, Christina Y.
ASSISTANT EXAMINER: Gambel, Phillip
LEGAL REPRESENTATIVE: Lee, Wendy M.
NUMBER OF CLAIMS: 37
EXEMPLARY CLAIM: 1,19
NUMBER OF DRAWINGS: 11 Drawing Figure(s); 10 Drawing Page(s)
LINE COUNT: 1757
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 18 OF 25 USPATFULL

TI Biologically active acylated amino acid derivatives

AB The present invention relates to novel compounds which possess a broad range of useful biological activities. These compounds can maintain, increase, or restore sensitivity of cells to therapeutic or prophylactic agents. They can also suppress, modify, or significantly reduce an immune response, including an autoimmune response in a mammal. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well-suited for treatment of multi-drug resistant cells, for prevention of the development of multi-drug resistance, for use in multi-drug resistant cancer therapy, and for prevention or treatment of graft rejection and various autoimmune diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 97:31693 USPATFULL
TITLE: Biologically active acylated amino acid derivatives
INVENTOR(S): Armistead, David M., Maynard, MA, United States
Saunders, Jeffrey O., Acton, MA, United States
Boger, Joshua S., Concord, MA, United States
PATENT ASSIGNEE(S): Vertex Pharmaceuticals Incorporated, Cambridge, MA, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5620971	19970415
APPLICATION INFO.:	US 1994-217982	19940325 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1992-881152, filed on 11 May 1992, now abandoned And a continuation-in-part of Ser. No. US 1993-127814, filed on 28 Sep 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-952299, filed on 28 Sep 1992, now abandoned , said Ser. No. US -881152 which is a continuation-in-part of Ser. No. US 1991-697785, filed on 9 May 1991, now abandoned

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Grumbling, Matthew V.
LEGAL REPRESENTATIVE: Fish & Neave; Haley, Jr., James F.; Marks, Andrew S.
NUMBER OF CLAIMS: 27
EXEMPLARY CLAIM: 1
LINE COUNT: 3425
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 19 OF 25 USPATFULL
TI Methods for inducing site-specific immunosuppression and compositions of
site specific immunosuppressants
AB The present invention provides methods and formulations for site-specific immune suppression of immune/inflammatory responses with localized or topical application of immunosuppressants including cyclosporines, rapamycins (RPM), or combinations of immunosuppressants and anti-inflammatory compounds. Methods for the use of said formulations to effect site-specific immune suppression of local inflammatory/immune responses in mammalian tissue and for treatment of autoimmune, T-cell mediated immune disease, inflammatory conditions, inhibition of contact hypersensitivity, and for producing prolonged skin
allograft survival, and wound healing are presented. In addition, methods for use of said formulations--in tandem with systemic applications of immunosuppressant such as cyclosporine or without same--are presented. The present invention also relates to alternative formulations and delivery systems for the efficacious treatment of the aforementioned conditions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	96:67755 USPATFULL
TITLE:	Methods for inducing site-specific immunosuppression and compositions of site specific immunosuppressants
INVENTOR(S):	Hewitt, Charles W., 698 Tranquility Turn, Marlton, NJ, United States 08053 Black, Kirby S., 13401 Sussex Pl., Santa Ana, CA, United States 92705
PATENT ASSIGNEE(S):	Hewitt, Charles W., Marlton, NJ, United States (U.S. individual) Black, Kirby S., Acworth, GA, United States (U.S. individual)

	NUMBER	DATE
PATENT INFORMATION:	US 5540931	19960730
APPLICATION INFO.:	US 1994-265471	19940624 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1992-879889, filed on 7 May 1992, now abandoned which is a continuation of Ser. No. US 1991-637056, filed on 3 Jan 1991, now abandoned which is a division of Ser. No. US 1989-318676, filed on 3 Mar 1989, now patented, Pat. No. US 4996193, issued on 26 Feb 1991	
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Kishore, Gollamudi S.	
LEGAL REPRESENTATIVE:	Robbins, Berliner & Carson	
NUMBER OF CLAIMS:	9	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	24 Drawing Figure(s); 18 Drawing Page(s)	
LINE COUNT:	1495	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 20 OF 25 USPATFULL
TI Immunosuppressive compounds
AB This invention relates to a novel class of immunosuppressive compounds having an affinity for the FK-506 binding protein (FKBP). Once bound to this protein, the immunosuppressive compounds inhibit the prolyl peptidyl cis-trans isomerase (rotamase) activity of the FKBP and inhibit
T cell activation. As such, the compounds of this invention can be used as immunosuppressive drugs to prevent or significantly reduce graft rejection in bone marrow and organ transplantations and for use in the

treatment of a wide variety of autoimmune diseases in humans and other mammals.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	96:41236 USPATFULL
TITLE:	Immunosuppressive compounds
INVENTOR(S):	Armistead, David M., Maynard, MA, United States Boger, Joshua S., Concord, MA, United States Meyers, Harold V., Belmont, MA, United States Saunders, Jeffrey O., Acton, MA, United States Tung, Roger D., Cambridge, MA, United States
PATENT ASSIGNEE(S):	Vertex Pharmaceuticals, Incorporated, Cambridge, MA, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5516797	19960514
APPLICATION INFO.:	US 1994-226011	19940411 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1991-724734, filed on 2 Jul 1991, now patented, Pat. No. US 5330993 which is a continuation-in-part of Ser. No. US 1990-547814, filed on 2 Jul 1990, now patented, Pat. No. US 5192773

DOCUMENT TYPE:	Utility
PRIMARY EXAMINER:	O'Sullivan, Peter
LEGAL REPRESENTATIVE:	Haley, Jr., James F.; McDonell, Leslie A.; Marks, Andrew S.
NUMBER OF CLAIMS:	8
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	10 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT:	1452

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 21 OF 25 USPATFULL

TI Detection of immunosuppressants

AB A **method** of evaluating the immunosuppressive activity of a compound including contacting the compound with calcineurin and determining the ability of the compound to bind to the calcineurin. The ability to bind to the calcineurin is positively correlated to the immunosuppressive activity of the compound.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	94:97468 USPATFULL
TITLE:	Detection of immunosuppressants
INVENTOR(S):	Schreiber, Stuart L., Boston, MA, United States Friedman, Jeffrey S., Portola Valley, CA, United States Weissman, Irving L., Stanford, CA, United States Liu, Jun, Somerville, MA, United States
PATENT ASSIGNEE(S):	President and Fellows of Harvard College, Cambridge, MA, United States (U.S. corporation) Board of Trustees of the Leland Stanford Junior University, Palo Alto, CA, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5362629	19941108
APPLICATION INFO.:	US 1991-740175	19910805 (7)

DOCUMENT TYPE:	Utility
PRIMARY EXAMINER:	Wityshyn, Michael G.
ASSISTANT EXAMINER:	Leary, Louise N.
LEGAL REPRESENTATIVE:	Fish & Richardson
NUMBER OF CLAIMS:	1

EXEMPLARY CLAIM: 1
LINE COUNT: 727
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 22 OF 25 USPATFULL
TI Immunosuppressive compounds
AB This invention relates to a novel class of immunosuppressive compounds having an affinity for the FK-506 binding protein (FKBP). Once bound to this protein, the immunosuppressive compounds inhibit the prolyl peptidyl cis-trans isomerase (rotamass) activity of the FKBP and inhibit T cell activation. As such, the compounds of this invention can be used as immunosuppressive drugs to prevent or significantly reduce graft rejection in bone marrow and organ transplantations and for use in the treatment of a wide variety of autoimmune diseases in humans and other mammals.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 94:62454 USPATFULL
TITLE: Immunosuppressive compounds
INVENTOR(S): Armistead, David M., Maynard, MA, United States
Boger, Joshua S., Concord, MA, United States
Meyers, Harold V., Belmont, MA, United States
Saunders, Jeffrey O., Acton, MA, United States
Tung, Roger D., Cambridge, MA, United States
PATENT ASSIGNEE(S): Vertex Pharmaceuticals, Inc., Cambridge, MA, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5330993	19940719
APPLICATION INFO.:	US 1991-724734	19910702 (7)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1990-547814, filed on 2 Jul 1990, now patented, Pat. No. US 5192773
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Waddell, Frederick E.
ASSISTANT EXAMINER: Hook, Gregory
NUMBER OF CLAIMS: 1
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 10 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT: 1342
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 23 OF 25 USPATFULL
TI Use of ruthenium red as immunosuppressive agents
AB This invention relates to the use of Ruthenium Red as an immunosuppressive agent to prevent or significantly reduce graft rejection in organ and bone marrow transplantation. Ruthenium Red can also be used as an immunosuppressant drug for T lymphocyte mediated autoimmune diseases. Furthermore, Ruthenium Red may be useful in alleviating psoriasis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 93:69619 USPATFULL
TITLE: Use of ruthenium red as immunosuppressive agents
INVENTOR(S): Dwyer, Donard S., Lexington, MA, United States
Esenther, Kristin, Ashland, MA, United States
PATENT ASSIGNEE(S): Procept, Inc., Cambridge, MA, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5238689	19930824
APPLICATION INFO.:	US 1992-817536	19920107 (7)

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Cintins, Marianne M.
ASSISTANT EXAMINER: Cook, Rebecca
LEGAL REPRESENTATIVE: Hamilton, Brook, Smith & Reynolds
NUMBER OF CLAIMS: 5
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Figure(s); 1 Drawing Page(s)
LINE COUNT: 345
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 24 OF 25 USPATFULL
TI Immunosuppressive compounds
AB This invention relates to a novel class of immunosuppressive compounds having an affinity for the FK-506 binding protein (FKBP). Once bound to this protein, the immunosuppressive compounds inhibit the prolyl peptidyl cis-trans isomerase (rotamase) activity of the FKBP and inhibit T cell activation. As such, the compounds of this invention can be used as immunosuppressive drugs to prevent or significantly reduce graft rejection in bone marrow and organ transplantations and for use in the treatment of a wide variety of autoimmune diseases in humans and other mammals.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 93:18679 USPATFULL
TITLE: Immunosuppressive compounds
INVENTOR(S): Armistead, David A., Maynard, MA, United States
Boger, Joshua S., Concord, MA, United States
Meyers, Harold V., Lexington, MA, United States
Saunders, Jeffrey O., Littleton, MA, United States
Tung, Roger D., Cambridge, MA, United States
PATENT ASSIGNEE(S): Vertex Pharmaceuticals, Inc., Cambridge, MA, United States (U.S. corporation)

	NUMBER	DATE	
PATENT INFORMATION:	US 5192773	19930309	
APPLICATION INFO.:	US 1990-547814	19900702	(7)

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Ivy, C. Warren
ASSISTANT EXAMINER: Twardzik, Barbara
LEGAL REPRESENTATIVE: Hamilton, Brook, Smith & Reynolds
NUMBER OF CLAIMS: 10
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 10 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT: 956
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 25 OF 25 SCISEARCH COPYRIGHT 2000 ISI (R)
TI A tacrolimus-related immunosuppressant with biochemical properties distinct from those of tacrolimus
AB Background. Tacrolimus (FK506) is an **immunosuppressive drug** 50-100 times more potent than cyclosporine (CsA), the current mainstay of organ transplant rejection therapy. Despite being chemically unrelated, CsA and tacrolimus exert their immunosuppressive effects through the inhibition of calcineurin (CaN), a critical signaling molecule during T-lymphocyte activation. Although numerous clinical studies have proven the therapeutic efficacy of drugs within this class, tacrolimus and CsA also have a strikingly similar profile of unwanted side effects.
Method. Our objective has been to identify a less toxic immunosuppressant through the modification of ascomycin (FK520). Quantitative in vitro immunosuppression and toxicity assays have

demonstrated (see the accompanying article, p. 18) that we achieved our goal with L-732, 531 (indolyl-ascomycin; indolyl-ASC), a 32-O-(1-hydroxyethylindol-5-yl) ascomycin derivative with an improved therapeutic index relative to tacrolimus.

Results. We report that the attributes of indolyl-ASC may result from its distinctive biochemical properties. Ttl contrast to tacrolimus, indolyl-ASC binds poorly to FK506 binding protein 12 (FKBP12), the major cytosolic receptor for tacrolimus and related compounds. However, the stability of the interaction between the FKBP12-indolyl-ASC complex and CaN is much greater than that of the FKBP12-tacrolimus complex, These distinguishing properties of indolyl-ASC result in the potent inhibition of CaN within T lymphocytes but may lower the accumulation of the drug at sites of toxicity.

Conclusions. Indolyl-ASC may define those properties needed to increase the therapeutic efficacy of a macrolactam immunoregulant for treating both human **autoimmune disease** and organ transplant rejection.

ACCESSION NUMBER: 1998:86213 SCISEARCH
THE GENUINE ARTICLE: YR654
TITLE: A tacrolimus-related immunosuppressant with biochemical properties distinct from those of tacrolimus
AUTHOR: Peterson L B; Cryan J G; Rosa R; Martin M M; Wilusz M B; Sinclair P J; Wong F; Parsons J N; OKeefe S J; Parsons W H; Wyvratt M; Sigal N H; Williamson A R; Wiederrecht G J (Reprint)
CORPORATE SOURCE: MERCK & CO INC, MERCK SHARP & DOHME RES LABS, DEPT IMMUNOL RES, POB 2000, MAIL CODE R80 M-260B, RAHWAY, NJ 07065 (Reprint); MERCK & CO INC, MERCK SHARP & DOHME RES LABS, DEPT IMMUNOL RES, RAHWAY, NJ 07065; MERCK & CO INC, MERCK SHARP & DOHME RES LABS, DEPT MOL PHARMACOL, RAHWAY, NJ 07065; MERCK & CO INC, MERCK SHARP & DOHME RES LABS, DEPT MED CHEM, RAHWAY, NJ 07065; MERCK & CO INC, MERCK SHARP & DOHME RES LABS, DEPT MOL IMMUNOL, RAHWAY, NJ 07065
COUNTRY OF AUTHOR: USA
SOURCE: TRANSPLANTATION, (15 JAN 1998) Vol. 65, No. 1, pp. 10-18.
Publisher: WILLIAMS & WILKINS, 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436.
ISSN: 0041-1337.
DOCUMENT TYPE: Article; Journal
FILE SEGMENT: LIFE
LANGUAGE: English
REFERENCE COUNT: 29
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

Trying 3106016892...Open

Welcome to STN International! Enter x:x
LOGINID:ssspta1653hxp
PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1	Feb 2	Web Page URLs for STN Seminar Schedule - N. America
NEWS	2	Dec 17	Expanded CAplus Coverage of US, Japanese, WIPO, EPO, and German patents
NEWS	3	Feb 1	Addition of Machine-Translated Abstracts to CAplus
NEWS	4	Feb 28	Patent Information Now Searchable in CAOLD SDI/UPDATE SEARCH FIELD
NEWS	5	May 1	Beilstein Abstracts on STN - FILE BABS
NEWS	6	May 1	RN CROSSOVER AND ANSWER SIZE LIMITS INCREASED
NEWS	7	May 1	AIDSLINE has been reloaded
NEWS	8	May 1	Searching Y2-K compliant Patent Numbers
NEWS	9	May 9	Sequence Similarity Batch Search in DGENE
NEWS	10	May 19	Weekly Statistics for New Entries now available in INPADOC
NEWS	11	May 22	CITED REFERENCES NOW AVAILABLE IN CAPLUS AND CA FILE
NEWS	12	May 22	POSTPROCESSING OF SEARCH RESULTS MAY BE AFFECTED BY ADDITION OF CITED REFERENCES TO CAPLUS, CA, REGISTRY, CASREACT, MARPAT, and MARPATPREV
NEWS	13	Jun 2	KOREAN PATENTS NOW IN CAS DATABASES
NEWS	14	Jun 20	WIPO/PCT Patents Fulltext Database now on STN
NEWS	15	Jun 28	NEWS 15 Jun 28 CAS covers Web-distributed preprints

NEWS EXPRESS	FREE UPGRADE 5.0C NOW AVAILABLE
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 16:29:00 ON 02 JUL 2000

=> file uspat, biosis, medline

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.15	0.15

```
FILE 'USPATFULL' ENTERED AT 16:29:24 ON 02 JUL 2000
CA INDEXING COPYRIGHT (C) 2000 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 16:29:24 ON 02 JUL 2000
COPYRIGHT (C) 2000 BIOSIS(R)

FILE 'MEDLINE' ENTERED AT 16:29:24 ON 02 JUL 2000

=> e wu/au

E1            2     WTTEWAALL EVELAAR E W/AU
E2            1     WTTIG H J/AU
E3           81 --> WU/AU
E4          452     WU A/AU
E5            2     WU A A/AU
E6           10     WU A C/AU
E7            1     WU A C C/AU
E8            9     WU A C M/AU
E9            7     WU A D/AU
E10          16     WU A F/AU
E11           1     WU A FU/AU
E12          15     WU A G/AU

=> e wu,j/au

E1            1     WU ZUOQUAN/AU
E2            5     WU ZUZE/AU
E3            0 --> WU,J/AU
E4            5     WUAMETT J D/AU
E5            1     WUAMETT JAMES D/AU
E6            1     WUAN N/AU
E7            1     WUAN W T/AU
E8            1     WUAN XIANGMEI/AU
E9            2     WUANG G/AU
E10           1     WUANG LINGHUA/AU
E11           1     WUANG W E/AU
E12           1     WUANG WEILIN/AU

=> e wang, x/au

E1            1     WANG ZWEI PING M/AU
E2            1     WANG ZX/AU
E3            0 --> WANG, X/AU
E4            1     WANGA D B/AU
E5            2     WANGA O/AU
E6            1     WANGA X J/AU
E7           10     WANGAARD C/AU
E8            4     WANGAARD C H/AU
E9            3     WANGAARD D B/AU
E10           1     WANGABC JOACHIM/AU
E11           2     WANGAI A/AU
E12           3     WANGAI A W/AU

=> e wu, jiangping/au

E1            1     WU ZUOQUAN/AU
E2            5     WU ZUZE/AU
E3            0 --> WU, JIANGPING/AU
E4            5     WUAMETT J D/AU
E5            1     WUAMETT JAMES D/AU
E6            1     WUAN N/AU
E7            1     WUAN W T/AU
E8            1     WUAN XIANGMEI/AU
```

```
E9              2      WUANG G/AU
E10             1      WUANG LINGHUA/AU
E11             1      WU  G W E/AU
E12             1      WUANG WEILIN/AU

=> e wang, xin/au

E1              1      WANG ZWEI PING M/AU
E2              1      WANG ZX/AU
E3              0 --> WANG, XIN/AU
E4              1      WANGA D B/AU
E5              2      WANGA O/AU
E6              1      WANGA X J/AU
E7             10      WANGAARD C/AU
E8              4      WANGAARD C H/AU
E9              3      WANGAARD D B/AU
E10             1      WANGABO JOACHIM/AU
E11             2      WANGAI A/AU
E12             3      WANGAI A W/AU
```

DB Name	Query	Hit Count	Set Name
USPT	l21 and apotosis	4	L22
USPT	mitochondrial function adj disrutption	2628	L21
USPT	l19 and l18	8709	L20
USPT	immunosuppresive drug adn l17	88660	L19
USPT	l17 and septic shock	117570	L18
USPT	l16 and inflammation	1745	L17
USPT	l15 and lymphocyte	3030	L16
USPT	l14 and neutrophil	5219	L15
USPT	l13 and blood cells	308616	L14
USPT	proteasome inhibitor adj method	828	L13
USPT	l11 and method	61	L12
USPT	l10 and l3	61	L11
USPT	l9 and l4	244	L10
USPT	l8 and l5	268	L9
USPT	l7 and l6	499	L8
USPT	immunosuppressive drug	88110	L7
USPT	rapamycin	531	L6
USPT	proteasome inhibitor	88388	L5
USPT	autoimmune disease	101671	L4
USPT	septic shock	119643	L3
USPT	lactocystin	0	L2
DWPI	wo-9922729-$.did.	1	L1

WEST

Help | Logout | Interrupt

Main Menu | Search Form | Posting Counts | Show S Numbers | Edit S Numbers | Preferences

Search Results -

Terms	Documents
l21 and apotosis	4

Database: US Patents Full-Text Database
JPO Abstracts Database
EPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Refine Search: `l21 and apotosis` Clear

Search History

Today's Date: 7/2/2000

WEST

Generate Collection

Search Results - Record(s) 1 through 1 of 1 returned.

☐ 1. Document ID: EP 967976 A1, WO 9922729 A1 , AU 9897318 A, CA 2219867 A1

L1: Entry 1 of 1 File: DWPI Jan 5, 2000

DERWENT-ACC-NO: 1999-313169
DERWENT-WEEK: 200006

TITLE: Composition containing inhibitor of proteasome

INVENTOR: WANG, X; WU, J

PRIORITY-DATA:
1997CA-2219867 October 31, 1997

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
EP 967976 A1	January 5, 2000	E	000	A61K031/40
WO 9922729 A1	May 14, 1999	E	105	A61K031/40
AU 9897318 A	May 24, 1999	N/A	000	A61K031/40
CA 2219867 A1	April 30, 1999	E	000	A61K031/40

INT-CL (IPC): A61K 31/40; A61K 31/71; A61K 38/13; C12Q 1/37

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw Desc | Image

Generate Collection

Terms	Documents
wo-9922729-$.did.	1

Display 10 Documents, starting with Document: 1

Display Format: CIT Change Format

WEST

Generate Collection

Search Results - Record(s) 1 through 4 of 4 returned.

☐ 1. Document ID: US 6001553 A

L22: Entry 1 of 4 File: USPT Dec 14, 1999

US-PAT-NO: 6001553
DOCUMENT-IDENTIFIER: US 6001553 A

TITLE: Functional expression of mammalian adenylyl cyclase in yeast

DATE-ISSUED: December 14, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Broach; James R.	Princeton	NJ	N/A	N/A
Manfredi; John P.	Ossining	NY	N/A	N/A
Trueheart; Joshua	Nyack	NY	N/A	N/A

US-CL-CURRENT: 435/4; 435/232, 435/252.2, 435/254.21

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw. Desc | Image

☐ 2. Document ID: US 5994076 A

L22: Entry 2 of 4 File: USPT Nov 30, 1999

US-PAT-NO: 5994076
DOCUMENT-IDENTIFIER: US 5994076 A

TITLE: Methods of assaying differential expression

DATE-ISSUED: November 30, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Chenchik; Alex	Palo Alto	CA	N/A	N/A
Jokhadze; George	Mountain View	CA	N/A	N/A
Bibilashvilli; Robert	Moscow	N/A	N/A	RUX

US-CL-CURRENT: 435/6; 435/91.1, 435/91.2, 536/23.1, 536/24.3, 536/24.31, 536/24.33

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw. Desc | Image

☐ 3. Document ID: US 5837837 A

L22: Entry 3 of 4 File: USPT Nov 17, 1998

US-PAT-NO: 5837837
DOCUMENT-IDENTIFIER: US 5837837 A

TITLE: Nucleic acids molecules encoding Caspase-8h and Caspase-8i

DATE-ISSUED: November 17, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hunter; John J.	Cambridge	MA	N/A	N/A
Shyjan; Andrew W.	Nahant	MA	N/A	N/A
Wong; Grace H. W.	Brookline	MA	N/A	N/A

US-CL-CURRENT: 536/23.1; 530/300, 530/350

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw Desc | Image

☐ 4. Document ID: US 5672686 A

L22: Entry 4 of 4 File: USPT Sep 30, 1997

US-PAT-NO: 5672686
DOCUMENT-IDENTIFIER: US 5672686 A

TITLE: Bcl-Y - specific antibodies

DATE-ISSUED: September 30, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Chittenden; Thomas D.	Brookline	MA	N/A	N/A

US-CL-CURRENT: 530/387.9; 530/388.2, 530/389.1, 530/391.3

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw Desc | Image

Generate Collection

Terms	Documents
l21 and apotosis	4

Display 10 Documents, starting with Document: 4

Display Format: CIT Change Format

Trying 3106016892...Open

Welcome to STN International! Enter x:x
LOGINID:ssspta1653hxp
PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1	Feb 2	Web Page URLs for STN Seminar Schedule - N. America
NEWS	2	Dec 17	Expanded CAplus Coverage of US, Japanese, WIPO, EPO, and German patents
NEWS	3	Feb 1	Addition of Machine-Translated Abstracts to CAplus
NEWS	4	Feb 28	Patent Information Now Searchable in CAOLD SDI/UPDATE SEARCH FIELD
NEWS	5	May 1	Beilstein Abstracts on STN - FILE BABS
NEWS	6	May 1	RN CROSSOVER AND ANSWER SIZE LIMITS INCREASED
NEWS	7	May 1	AIDSLINE has been reloaded
NEWS	8	May 1	Searching Y2-K compliant Patent Numbers
NEWS	9	May 9	Sequence Similarity Batch Search in DGENE
NEWS	10	May 19	Weekly Statistics for New Entries now available in INPADOC
NEWS	11	May 22	CITED REFERENCES NOW AVAILABLE IN CAPLUS AND CA FILE
NEWS	12	May 22	POSTPROCESSING OF SEARCH RESULTS MAY BE AFFECTED BY ADDITION OF CITED REFERENCES TO CAPLUS, CA, REGISTRY, CASREACT, MARPAT, and MARPATPREV
NEWS	13	Jun 2	KOREAN PATENTS NOW IN CAS DATABASES
NEWS	14	Jun 20	WIPO/PCT Patents Fulltext Database now on STN
NEWS	15	Jun 28	NEWS 15 Jun 28 CAS covers Web-distributed preprints

NEWS EXPRESS	FREE UPGRADE 5.0C NOW AVAILABLE
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 15:00:14 ON 02 JUL 2000

=> file medline, biosis, uspat, wpids, hcaplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.15	0.15

FILE 'MEDLINE' ENTERED AT 15:00:34 ON 02 JUL 2000

FILE 'BIOSIS' ENTERED AT 15:00:34 ON 02 JUL 2000
COPYRIGHT (C) 2000 BIOSIS(R)

FILE 'USPATFULL' ENTERED AT 15:00:34 ON 02 JUL 2000
CA INDEXING COPYRIGHT (C) 2000 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ENTERED AT 15:00:34 ON 02 JUL 2000
COPYRIGHT (C) 2000 DERWENT INFORMATION LTD

FILE 'HCAPLUS' ENTERED AT 15:00:34 ON 02 JUL 2000
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2000 AMERICAN CHEMICAL SOCIETY (ACS)

=> s proteasome inhibitor

L1 912 PROTEASOME INHIBITOR

=> s lactocystin

L2 2 LACTOCYSTIN

=> s autoimmune disease

L3 26758 AUTOIMMUNE DISEASE

=> s graft rejectin

L4 0 GRAFT REJECTIN

=> s l3 and l2

L5 2 L3 AND L2

=> s l5 and l1

L6 2 L5 AND L1

=> d l6 ti abs ibib tot

L6 ANSWER 1 OF 2 WPIDS COPYRIGHT 2000 DERWENT INFORMATION LTD
TI Composition containing inhibitor of proteasome.
AN 1999-313169 [26] WPIDS
AB WO 9922729 A UPAB: 19990707
NOVELTY - Composition for (i) reversing an on-going adverse immune response, (ii) disrupting mitochondrial function or (iii) disrupting nitric oxide synthesis contains a **proteasome inhibitor** (I).

DETAILED DESCRIPTION - An INDEPENDENT CLAIM is also included for a method of screening for (I) by treating a mammalian cell lysate that contains proteasomes with a labeled peptide substrate; treating the mixture with a test compound and measuring the amount of label released from the substrate, in presence and absence of test compound. Absence, or reduction in the amount, of released label shows the test compound to be an inhibitor.

ACTIVITY - Immunosuppressant; anticancer; anti-inflammatory.

MECHANISM OF ACTION - (I) (i) reduces activation of T cells; (ii) disrupts mitochondrial function by blocking electron transport and/or inducing cytochrome C leakage from the mitochondria, resulting in caspase activation and apoptosis; (iii) inhibits nitric oxide synthase. The

proteasome is essential for (i) progression of T cells from the G0 to S1 phases; (ii) for electron transport in mitochondria; (iii) for upregulation of interleukin-1receptor alpha ; (iv) for function of cyclin-dependent kinase (CDK) 2 but not CDK4; (v) for degradation of cyclin E but not cyclin A.

USE - (I) is used (a) to treat **autoimmune disease** and graft rejection, administered after activation of T cells: (b) to treat diseases associated with high mitochondrial activity, especially cancer, inflammation, adverse immune reactions and hyperthyroidism and (c) to treat conditions associated with expression of nitric oxide synthase, particularly inflammation and septic shock.

ADVANTAGE - (I) induce apoptosis in activated (leukemic or antigen specific), but not resting, T cells. The effect of (I) is rapid and reversible. T cells, either resting or stimulated 40 hr earlier with phytohemagglutinin, were cultured in presence of 10 micro M **lactocystin**, and after a further 24 hr analyzed for viability by trypan blue exclusion. Viability for the stimulated cells was only 46% of that for untreated controls, but for treated, resting cells viability was 87% of that for the controls.

ACCESSION NUMBER: 1999-313169 [26] WPIDS
DOC. NO. CPI: C1999-092489
TITLE: Composition containing inhibitor of proteasome.
DERWENT CLASS: B05
INVENTOR(S): WANG, X; WU, J
PATENT ASSIGNEE(S): (UYMO-N) UNIV MONTREAL CENT RECH CENT HOSPITALIER; (WANG-I) WANG X; (WUJJ-I) WU J
COUNTRY COUNT: 83
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 9922729	A1	19990514	(199926)*	EN	105
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL OA PT SD SE SZ UG ZW					
W: AL AM AT AU AZ BA BB BG BR BY CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW					
AU 9897318	A	19990524	(199940)		
CA 2219867	A1	19990430	(199941)	EN	
EP 967976	A1	20000105	(200006)	EN	
R: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE					

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 9922729	A1	WO 1998-CA1010	19981029
AU 9897318	A	AU 1998-97318	19981029
CA 2219867	A1	CA 1997-2219867	19971031
EP 967976	A1	EP 1998-951135	19981029
		WO 1998-CA1010	19981029

FILING DETAILS:

PATENT NO	KIND		PATENT NO
AU 9897318	A	Based on	WO 9922729
EP 967976	A1	Based on	WO 9922729

PRIORITY APPLN. INFO: CA 1997-2219867 19971031

L6 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2000 ACS

TI The use of proteasome inhibitors for treating cancer, inflammation, **autoimmune disease**, graft rejection and septic shock, and screening method

AB The present invention relates to compns. comprising proteasome inhibitors, such as **lactocystin** and analogs thereof. These compns. are used for the following purposes: (1) to disrupt mitochondrial function (useful against cancer, inflammation, adverse immune reaction and hyperthyroidism), (2) to disrupt nitric oxide synthesis (useful against inflammation and septic shock), and (3) to reverse ongoing adverse immune reactions, such as autoimmune diseases and graft rejection. In the latter case, the compns. are administered once the patient's T cells are mostly activated. Proteasome inhibitors can also be combined with immunosuppressive drugs, e.g. rapamycin, cyclosporin A, and FK506. Finally, a method for screening a compd. having a proteasome inhibition activity is also disclosed and claimed.

ACCESSION NUMBER: 1999:311103 HCAPLUS
DOCUMENT NUMBER: 130:332911
TITLE: The use of proteasome inhibitors for treating cancer, inflammation, **autoimmune disease**, graft rejection and septic shock, and screening method
INVENTOR(S): Wu, Jiangping; Wang, Xin
PATENT ASSIGNEE(S): Centre de Recherche du Centre Hospitalier de l'Universite de Montreal, Can.
SOURCE: PCT Int. Appl., 106 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9922729	A1	19990514	WO 1998-CA1010	19981029
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9897318	A1	19990524	AU 1998-97318	19981029
EP 967976	A1	20000105	EP 1998-951135	19981029
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				

PRIORITY APPLN. INFO.: CA 1997-2219867 19971031
WO 1998-CA1010 19981029

REFERENCE COUNT: 15
REFERENCE(S):
(1) Conner, E; JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS 1997, V282(3), P1615 HCAPLUS
(2) Cui, H; PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 1997, V94(14), P7515 HCAPLUS
(3) Griscavage, J; PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 1996, V93(8), P3308 HCAPLUS
(6) Hirsch, T; JOURNAL OF IMMUNOLOGY 1998, V161(1), P35 HCAPLUS
(7) Imajoh-Ohmi, S; BIOCHEMICAL AND BIOPHYSICAL

```
=> s rapamycin

L7        5980 RAPAMYCIN

=> s lactocystin

L8           2 LACTOCYSTIN

=> s l7 and l8

L9           1 L7 AND L8

=> d l9 ti abs ibib tot
```

L9 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2000 ACS

TI The use of proteasome inhibitors for treating cancer, inflammation, autoimmune disease, graft rejection and septic shock, and screening method

AB The present invention relates to compns. comprising proteasome inhibitors, such as **lactocystin** and analogs thereof. These compns. are used for the following purposes: (1) to disrupt mitochondrial function (useful against cancer, inflammation, adverse immune reaction and hyperthyroidism), (2) to disrupt nitric oxide synthesis (useful against inflammation and septic shock), and (3) to reverse ongoing adverse immune reactions, such as autoimmune diseases and graft rejection. In the latter case, the compns. are administered once the patient's T cells are mostly activated. Proteasome inhibitors can also be combined with immunosuppressive drugs, e.g. **rapamycin**, cyclosporin A, and FK506. Finally, a method for screening a compd. having a proteasome inhibition activity is also disclosed and claimed.

ACCESSION NUMBER:	1999:311103 HCAPLUS
DOCUMENT NUMBER:	130:332911
TITLE:	The use of proteasome inhibitors for treating cancer, inflammation, autoimmune disease, graft rejection and septic shock, and screening method
INVENTOR(S):	Wu, Jiangping; Wang, Xin
PATENT ASSIGNEE(S):	Centre de Recherche du Centre Hospitalier de l'Universite de Montreal, Can.
SOURCE:	PCT Int. Appl., 106 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9922729	A1	19990514	WO 1998-CA1010	19981029

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 9897318 A1 19990524 AU 1998-97318 19981029
EP 967976 A1 20000105 EP 1998-951135 19981029
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI
PRIORITY APPLN. INFO.: CA 1997-2219867 19971031
WO 1998-CA1010 19981029

REFERENCE COUNT: 15
REFERENCE(S):
(1) Conner, E; JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS 1997, V282(3), P1615 HCAPLUS
(2) Cui, H; PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 1997, V94(14), P7515 HCAPLUS
(3) Griscavage, J; PROCEEDINGS OF THE NATIONAL ACADEMY
OF SCIENCES OF THE UNITED STATES OF AMERICA 1996, V93(8), P3308 HCAPLUS
(6) Hirsch, T; JOURNAL OF IMMUNOLOGY 1998, V161(1), P35 HCAPLUS
(7) Imajoh-Ohmi, S; BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS 1995, V217(3), P1070 HCAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT